Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

The agency turned down use of Roche’s Perjeta (pertuzumab) for the adjuvant treatment of early stage breast cancer as well as Pfizer’s Xtandi (enzalutamide) for early-stage prostate cancer ...